Solid Tumors clinical trials in Utah
124 active Solid Tumors trials with a site in Utah. Describe your situation to see which ones look like a fit.
- First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
- A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
- SNV1521 in Participants With Advanced Solid Tumors
- PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
- Study in Advanced Solid Tumor Patients
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
- Pan Tumor Rollover Study
- A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
- Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
- Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
- First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
- Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
- A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
- Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
- A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- Study of CHS-114 in Participants With Advanced Solid Tumors
- First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
- QTX3034 in Patients With KRAS G12D Mutation
- A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
- Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
- Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
- A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
- JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
- A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.